Patisiran, Inotersen Aid Hereditary Transthyretin Amyloidosis

THURSDAY, July 5, 2018 -- For patients with hereditary transthyretin amyloidosis with polyneuropathy, an investigational RNA interference therapeutic agent (patisiran) and a 2 ' -O-methoxyethyl-modified antisense oligonucleotide (inotersen), which...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news